NCT01741727View on ClinicalTrials.gov

A Study of ABT-414 in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Squamous Cell Tumors
Interventions
DRUG

ABT-414

ABT-414 will be administered by intravenous infusion.

Trial Locations (6)

60637

Site Reference ID/Investigator# 83156, Chicago

78229

Site Reference ID/Investigator# 83155, San Antonio

85258

Site Reference ID/Investigator# 90333, Scottsdale

02215

Site Reference ID/Investigator# 117516, Boston

Site Reference ID/Investigator# 83154, Boston

K1H 8L6

Site Reference ID/Investigator# 89035, Ottawa

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01741727 - A Study of ABT-414 in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter